Remarks — Despite the absence of published clinical trials for the use of LORS, the GDG recommended extending this life-saving recommendation to children 5–10 years of age. The recommendation was based on an analysis of the biological plausibility of LORS being efficacious in this age group, the lack of any evidence of safety concerns, and the experience of medical professionals of the effectiveness and safety of LORS in this population. This benefit-risk assessment was sufficient for the GDG to recommend extending the age range of the current recommendation.